ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023
2024年4月30日 - 3:00PM
ビジネスワイヤ(英語)
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage
biotechnology company focused on the development of glenzocimab, an
innovative drug for the treatment of cardiovascular emergencies,
announces the postponement of the publication of its annual results
and universal registration document including its 2023 annual
financial report, originally scheduled for April 30, 2024.
On April 29, 2024, the Company's Board of Directors decided on
this postponement in order to take into account the consequences of
the recent results of its ACTISAVE phase 2/3 trial in the treatment
of acute ischemic stroke and the Company's new strategic
options.
The Company will issue a press release announcing the new date
of approval and publication of the 2023 financial statements by the
Board of Directors, as well as that of the annual financial report
included in the 2023 Universal Registration Document.
Depending on the date of publication of the financial
statements, the date of the Annual General Meeting, initially
scheduled for June 21, 2024, may be postponed. If necessary, this
information will also be announced in a press release.
As announced on April 25, 2024, when the ACTISAVE trial results
have been published, the Company is able to finance its operations
until October 2024.
About ACTICOR BIOTECH
Acticor Biotech is a clinical-stage biopharmaceutical company
developing glenzocimab, an innovative drug for the treatment of
cardiovascular emergencies, particularly ischemic stroke.
Positive results from the phase 1b/2a study, ACTIMIS, published
in January 2024 in the Lancet Neurology (link to publication)
confirmed the safety profile of glenzocimab and showed a reduction
in mortality and intracerebral haemorrhage in the
glenzocimab-treated group of stroke patients. A post-hoc analysis
of brain imaging at 0 and 24 hours using artificial intelligence
confirmed these results, showing a reduction in the number and
volume of intracerebral lesions in patients treated with
glenzocimab.
On April 25, 2024, the company announced the initial results of
the ACTISAVE trial (NCT05070260), an international phase 2/3 study
in the treatment of acute ischemic stroke, which showed no efficacy
of glenzocimab on the primary endpoint, the proportion of patients
with severe disability or death (mRS 4-6) 90 days after stroke, nor
on the secondary endpoint, the proportion of patients returning to
life without disability (mRS 0-2) 90 days after stroke. The
presentation of the study's main results will take place on May 15,
2024 at a plenary session of the European Stroke Organization
Conference (ESOC).
Acticor Biotech is currently investigating any influencing
factors that may have accounted for these results, which contradict
the findings of pharmacology studies and previous clinical
data.
Acticor Biotech is backed by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation)
and has been listed on Euronext Growth Paris since November 2021
(ISIN: FR0014005OJ5 - ALACT).
For further information, please visit:
https://www.acticor-biotech.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429031915/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com
Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com
NewCap Mathilde BOHIN Investor Relations
acticor@newcap.eu T.: +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
過去 株価チャート
から 6 2024 まで 7 2024
Acticor Biotech (EU:ALACT)
過去 株価チャート
から 7 2023 まで 7 2024